Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Implied Volatility Surging for Ascendis Pharma (ASND) Stock Options
09:47am, Wednesday, 30'th Dec 2020
Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.
Ascendis Pharma A/S Announces Planned Board Transition
04:05pm, Monday, 14'th Dec 2020
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
07:05am, Wednesday, 25'th Nov 2020
COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate
Ascendis Pharma: TransCon Platform Is A Major Value Driver
08:53pm, Tuesday, 17'th Nov 2020
Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
05:30pm, Wednesday, 11'th Nov 2020
– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –
Recap: Ascendis Pharma Q3 Earnings
04:24pm, Wednesday, 11'th Nov 2020
Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($2.70), w
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results
04:01pm, Wednesday, 11'th Nov 2020
– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –
COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
04:05pm, Monday, 02'nd Nov 2020
COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne
Goldman Sachs Group Upgrades Chr. Hansen Holding A/S (OTCMKTS:CHYHY) to Neutral
02:54am, Thursday, 22'nd Oct 2020
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) was upgraded by research analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports. A nu
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given Consensus Recommendation of “Hold” by Analysts
03:14am, Wednesday, 21'st Oct 2020
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) has been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Three equities research analyst
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
12:00am, Friday, 16'th Oct 2020
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $176.50
05:44am, Thursday, 15'th Oct 2020
Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus rating of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst ha
Nuveen Asset Management LLC Has $1.79 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)
08:14am, Wednesday, 14'th Oct 2020
Nuveen Asset Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The
$1.94 Million in Sales Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter
04:30am, Wednesday, 14'th Oct 2020
Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to post sales of $1.94 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for
